(Q84903953)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

title

The follow-up of women at high risk for breast cancer relapse (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

2

Susana Banerjee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Ian E Smith

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

18 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

S74-7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Routine follow up of breast cancer in primary care: randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Intensive vs Clinical Follow-up After Treatment of Primary Breast Cancer: 10-Year Update of a Randomized Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Economic impact of harmonizing medical practices: compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Survivors of childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Doc, shouldn't we be getting some tests?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Detection and clinical relevance of micrometastatic cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Circulating tumour cells in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Emerging molecular markers of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Detection and quantification of mutations in the plasma of patients with colorectal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Circulating mutant DNA to assess tumor dynamics

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Prediction of breast tumor progression by integrity of free circulating DNA in serum.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Brain metastases: the HER2 paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

1 reference

7 January 2021

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Primary breast cancer phenotypes associated with propensity for central nervous system metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Survival after brain metastases from breast cancer in the trastuzumab era.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Aust

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Is breast cancer survival improving?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-9776%2809%2970277-2

7 January 2021

10.1016/S0960-9776(09)70277-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19914547%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference